Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
11/2000
11/23/2000WO2000069849A1 Pyrazole carboxamides useful for the treatment of obesity and other disorders
11/23/2000WO2000069848A1 Compounds having cytokine inhibitory activity
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069846A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000WO2000069836A1 Short-acting benzodiazepines
11/23/2000WO2000069834A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/23/2000WO2000069832A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000WO2000069826A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000WO2000069821A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069819A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000WO2000069816A1 Metabotropic glutamate receptor antagonists
11/23/2000WO2000069433A1 Antagonists of gonadotropin releasing hormone
11/23/2000WO2000069424A2 Method of treating psychotic disorders
11/23/2000WO2000036918A9 Methods and compositions for treatment of cell proliferative disorders
11/23/2000WO2000013681A3 4-quinolinemethanol derivatives as purine receptor antagonists (i)
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000DE19922825A1 Neue fluortriazinhaltige brillantgelbe Farbstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zum Färben von hydroxy- und amidgruppenhaltigen Materialien New fluortriazinhaltige brilliant yellow dyes, processes for their preparation and their use for dyeing hydroxyl- and amido-containing materials
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2373855A1 Method of treating psychotic disorders
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373510A1 Pyrazole carboxamides useful for the treatment of obesity and other disorders
11/23/2000CA2373509A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372617A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372429A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000CA2372273A1 Reactive dye compounds
11/23/2000CA2372224A1 Transition metal complexes and olefin polymerization process
11/22/2000EP1054041A1 Brilliant yellow dyes containing a fluorotriazine group, process for their preparation and their use for dyeing materials containing hydroxy- and amido-groups
11/22/2000EP1054005A1 Sulfonamide derivatives, process for producing the same and utilization thereof
11/22/2000EP1054004A1 Novel pyrimidine-5-carboxamide derivatives
11/22/2000EP1054003A1 Urocanic acid derivatives
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053230A1 Triazine antiviral compounds
11/22/2000EP1053227A1 Ppar-gamma modulators
11/22/2000EP1053224A1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament
11/22/2000EP1052992A1 Cyclic amine modulators of chemokine receptor activity
11/22/2000EP0726267B1 Quinazoline derivatives
11/22/2000CN1274353A Halogen substituted tetracyclic tetrahydrofuran derivatives
11/22/2000CN1274283A Quinoline-containing & Alpha;-ketoamide cysteine and serine protease inhibitors
11/22/2000CN1058713C Process for prepn. of aminotriazine derivatives
11/22/2000CN1058712C Microbicidal triazolyl derivatives
11/22/2000CN1058710C Benzamide derivatives, process for prepn. thereof and pharmaceutical compsn. comprising same
11/22/2000CN1058709C Amide compounds for medical treatment
11/21/2000US6150557 Compounds
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150527 Synthetic multimerizing agents
11/21/2000US6150526 Piperidine derivative having renin inhibiting activity
11/21/2000US6150523 Process for preparing imidazoquinolinamines
11/21/2000US6150382 Enzyme inhibitors of blood coagulation factor xa, a serine protease class of enzymes; e.g., 4-hydroxy-3-((4-(2-carboxy-methyl)thio-6-(3-(1-methyl)-6-(3-(1 -methyl)imidazolin-2-yl)-phenoxy-3,5-difluoropyridine and derivatives
11/21/2000US6150380 Crystalline form of omeprazole
11/21/2000US6150379 Compounds and compositions as anticoagulants
11/21/2000US6150377 Farnesyl protein transferase inhibitors; anticarcinogenic,-tumor and -proliferative agents; also psoriasis, benign prostatic hypertrophy or restinosis; infections facilitated by farnesyl protein transferase, e.g., malaria or hepatitus delta
11/21/2000US6150375 Inhibitors of both of the human 5ar isozymes; benign prostate hyperplasia, male pattern baldness, acne vulgaris, seborrhea, androgenic alopecia, hirsutism and prostate cancer; blocks the conversion of testosterone to 5-alpha-dihydrotestosterone
11/21/2000US6150365 Anxiety method
11/21/2000US6150362 Administering 1,3,5-substituted triazine compounds to the patient suffering from angiogenic diseases
11/21/2000US6150356 Potassium channel inhibitors and method
11/21/2000US6150355 Phenylpiperidine derivative
11/21/2000US6150352 Antagonists of gonadotropin releasing hormone
11/21/2000US6149890 Chelated complexes of paramagnetic metals with low toxicity
11/21/2000CA2093433C Sertindole prodrugs
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068222A2 Solvates of pymetrozine
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068208A1 Pyrimidinones derivatives for the treatment of atherosclerosis
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068202A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000WO2000068201A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068200A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068199A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068197A1 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068185A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000WO2000067847A2 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
11/16/2000WO2000067801A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000035887A3 Vitronectin receptor antagonist pharmaceuticals
11/16/2000WO2000034437A3 Inhibitors of prenyl-protein transferase
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000CA2373182A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2373035A1 3a,4,5,9b-tetrahydro-1h-benz¬e|indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2372663A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2371472A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000CA2371469A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2370838A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000CA2368831A1 Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/15/2000EP1052255A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics.
11/15/2000EP1052254A1 Nitrogenous heterocyclic derivatives and medicine thereof
11/15/2000EP1052238A1 Novel tricyclic compound
11/15/2000EP1051415A1 Benzamide derivatives as vasopressin antagonists
1 ... 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 ... 1080